- Phare
- Validé par KD/KO
Anticorps Polyclonal de lapin anti-PKC Iota
PKC Iota Polyclonal Antibody for WB, IHC, IF/ICC, FC (Intra), IP, ELISA
Hôte / Isotype
Lapin / IgG
Réactivité testée
Humain et plus (2)
Applications
WB, IHC, IF/ICC, FC (Intra), IP, CoIP, ELISA
Conjugaison
Non conjugué
N° de cat : 13883-1-AP
Synonymes
Galerie de données de validation
Applications testées
| Résultats positifs en WB | cellules HeLa, cellules MCF-7 |
| Résultats positifs en IP | cellules HeLa, |
| Résultats positifs en IHC | tissu de cancer du sein humain, tissu de cancer du poumon humain il est suggéré de démasquer l'antigène avec un tampon de TE buffer pH 9.0; (*) À défaut, 'le démasquage de l'antigène peut être 'effectué avec un tampon citrate pH 6,0. |
| Résultats positifs en IF/ICC | cellules HeLa, |
| Résultats positifs en FC (Intra) | cellules HeLa, |
Dilution recommandée
| Application | Dilution |
|---|---|
| Western Blot (WB) | WB : 1:1000-1:6000 |
| Immunoprécipitation (IP) | IP : 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate |
| Immunohistochimie (IHC) | IHC : 1:50-1:500 |
| Immunofluorescence (IF)/ICC | IF/ICC : 1:200-1:800 |
| Flow Cytometry (FC) (INTRA) | FC (INTRA) : 0.20 ug per 10^6 cells in a 100 µl suspension |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, check data in validation data gallery | |
Applications publiées
| KD/KO | See 4 publications below |
| WB | See 7 publications below |
| IHC | See 5 publications below |
| IF | See 4 publications below |
| IP | See 1 publications below |
| CoIP | See 1 publications below |
Informations sur le produit
13883-1-AP cible PKC Iota dans les applications de WB, IHC, IF/ICC, FC (Intra), IP, CoIP, ELISA et montre une réactivité avec des échantillons Humain
| Réactivité | Humain |
| Réactivité citée | Humain, poulet, souris |
| Hôte / Isotype | Lapin / IgG |
| Clonalité | Polyclonal |
| Type | Anticorps |
| Immunogène | PKC Iota Protéine recombinante Ag4990 |
| Nom complet | protein kinase C, iota |
| Masse moléculaire calculée | 68 kDa |
| Poids moléculaire observé | 67 kDa |
| Numéro d’acquisition GenBank | BC022016 |
| Symbole du gène | PKC Iota |
| Identification du gène (NCBI) | 5584 |
| Conjugaison | Non conjugué |
| Forme | Liquide |
| Méthode de purification | Purification par affinité contre l'antigène |
| Tampon de stockage | PBS with 0.02% sodium azide and 50% glycerol |
| Conditions de stockage | Stocker à -20°C. Stable pendant un an après l'expédition. L'aliquotage n'est pas nécessaire pour le stockage à -20oC Les 20ul contiennent 0,1% de BSA. |
Informations générales
The atypical protein kinase C isoform PRKC iota (PRKCI) is a member of the protein kinase C (PKC) family of serine/threonine protein kinases. PKC family comprises at least eight members, which are differentially expressed and are involved in a wide variety of cellular processes. PRKC iota is calcium-independent and phospholipid-dependent. It is not activated by phorbolesters or diacylglycerol. This kinase can be recruited to vesicle tubular clusters (VTCs) by direct interaction with the small GTPase RAB2, where this kinase phosphorylates glyceraldehyde-3-phosphate dehydrogenase (GAPD/GAPDH) and plays a role in microtubule dynamics in the early secretory pathway. This kinase is found to be necessary for BCL-ABL-mediated resistance to drug-induced apoptosis and therefore protects leukemia cells against drug-induced apoptosis. PRKC iota plays a key role in cell proliferation, differentiation, and carcinogenesis, and it has been shown to be a human oncogene.
Protocole
| Product Specific Protocols | |
|---|---|
| WB protocol for PKC Iota antibody 13883-1-AP | Download protocol |
| IHC protocol for PKC Iota antibody 13883-1-AP | Download protocol |
| IF protocol for PKC Iota antibody 13883-1-AP | Download protocol |
| IP protocol for PKC Iota antibody 13883-1-AP | Download protocol |
| FC protocol for PKC Iota antibody 13883-1-AP | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
| Species | Application | Title |
|---|---|---|
Mol Cancer circPARD3 drives malignant progression and chemoresistance of laryngeal squamous cell carcinoma by inhibiting autophagy through the PRKCI-Akt-mTOR pathway.
| ||
Development Coupling of apical-basal polarity and PCP to interpret the Wnt signaling gradient and orient feather branch.
| ||
Mol Med Paired protein kinases PRKCI-RIPK2 promote pancreatic cancer growth and metastasis via enhancing NF-κB/JNK/ERK phosphorylation | ||
Int J Biol Sci Poly (ADP-ribose) polymerase 1 (PARP1) inhibition promotes pulmonary metastasis of osteosarcoma by boosting ezrin phosphorylation. | ||
Onco Targets Ther Protein kinase C-iota-mediated glycolysis promotes non-small-cell lung cancer progression.
| ||
Antioxidants (Basel) PKCiota Inhibits the Ferroptosis of Esophageal Cancer Cells via Suppressing USP14-Mediated Autophagic Degradation of GPX4
|








